GCIHybridan Small Cap Feast: 19/07/24
* A corporate client of Hybridan LLP
** Arranged by type of listing and date of announcement
*** Alphabetically arranged
**** Potential means Intention to Float (ITF) has been announced, or it is a rumour
Dish of the day
What’s baking in the oven? **
Potential**** Initial Public Offerings:
ITF announced:
8th July 2024: Rome Resources: The Canada-based early-stage resource exploration Company has announced its intention to IPO on AIM in order to continue to make financial progress on its “Bisie North Tin Project”. The Company’s first day of trading on AIM is expected to be 26th July 2024. The Primary Offer expected size is approximately £4.0m.
The UK-based remote people monitoring technology company announces that its Independent Non-Executive Chair, Mr Simon Collins, has tendered his resignation from office as Chair of the Company. The Company thanks Mr Collins for his years of integral leadership through the Initial Public Offering on the AIM market in 2021 and the continued success of the business. The Company wishes him every success in his future endeavours. Commencement of the recruitment of a new Independent Non-Executive Chair to guide the Company through the next stage of its ambitious growth will begin immediately and in the meantime, Independent Non-Executive Director, Alexander Brennan, has assumed the role of Interim Chair of the Company.
The provider of software and services to the global publishing industry announces it has won three additional contracts across its Content and Commercial divisions. Within the Content division, the Company has won two follow-on contracts from existing customers, expanding the Edify business. These multiyear deals have a contract value, in aggregate, of more than £500k payable for works completed between three and five years. Within the Commercial division, the Company has also commenced work on a new three-year project to migrate, host and support an existing customer's Vista deployment onto our dedicated infrastructure. The contract value for this project is £1.4m over three years.
A gold producer in the Philippines announces its quarterly results for Q2 2024. Revenue increased to $46.7m (Q1 2024: $44.5m), cash flow increased to $24.8m (Q1 2024: 21.6m) and gold sales of 20,124 ounces sold at an average realised gold price of $2,320 per ounce (Q1 2024: 21,465 ounces at an average $2,069 per ounce). Company debt free following resolution of all debt disputes.
The clean water and clean air technology company transforming the environmental impact of industry announces that it has signed a Business Partnership Agreement with an 8a and HUBZone Certified Prime Contractor with the sole purpose of developing a mutually beneficial business relationship focused on the United States Department of Defense (DoD) funded PFAS remediation projects. HUBZone (Historically Under-utilized Business Zones) is administered by the SBA (Small Business Administration) and allows qualified businesses to be eligible to compete for the program's set-aside contracts within the DoD. DoD's estimated cost to investigate and clean up PFAS in Fiscal Year (FY) 2024 and beyond is $9.7 billion (estimate as of the end of FY 2023). This is a preliminary estimate that DoD expects will increase significantly as the ongoing investigations are completed and more information is known about the extent of the cleanup required.
The independent energy group focused on growth through gas, oil and renewable energy projects announces that further to the provisional award of three blocks as part of the 33rd UK offshore licensing round, the P2634 licence has now been formally awarded to Parkmead by the UK Government's North Sea Transition Authority (NSTA). This heavy oil accumulation has been proven by three wells and is estimated to contain oil-in-place of between 740 million and 1.33 billion barrels. The partnership will now begin to progress the approved three-year work programme to determine whether a technically and economically viable development can be delivered within the NSTA's Net Zero Strategy.
A commercial-stage medical device leader in advanced Magnetic Resonance Imaging (MRI) of lung function announces that it has entered into a trade-in agreement to exchange the University of Virginia Health System's (UVA Health) existing two research hyperpolarisers for two new clinical-grade hyperpolariser systems to be provided by Polarean. UVA Health is an integrated health system with a world-class academic medical center that includes a Level 1 Trauma Centre, an NCI-designated Comprehensive Cancer Center, and UVA Health Children's, the number one pediatric hospital in Virginia. UVA Health's Hyperpolarized Gas MR Imaging Center faculty pioneered the application of Xenon MRI for a variety of lung diseases, including asthma, cystic fibrosis, and bronchopulmonary dysplasia.
The transition energy company further to the update provided by the Company on 30 April 2024 and the continued discussions with Morocco's L'Office National des Hydrocarbures et des Mines (ONHYM), to provide a further update regarding further amendments to the Company's exploration permits at Anoual (the Additional Amendments), and entry into the optional Complementary Period under the exploration permits at Anoual. The Anoual exploration permits cover 8,873 square kilometres in Eastern Morocco, that ONHYM has now agreed, in place of the 18-month extension previously announced by the Company, on a longer 24-month extension to the initial period of the Anoual Exploration Permits, due to Force Majeure, ending on or about 7 January 2025.
The independent E&P company focused on Trinidad and Tobago, provides an update on operations for the three-month period ended 30 June 2024. Cash balance of $8.0m (unaudited) at 30 June 2024 versus $8.6m (unaudited) at 31 March 2024 and $11.3m (unaudited) at 30 June 2023. The Group had drawn borrowings (overdraft) of $3.0m at 30 June 2024 ( $4.0m at 31 March 2024 and $2.0m at 30 June 2023). Average realised oil price of $73.2/bbl for Q2 2024 (Q2 2023: $63.7/bbl; Q1 2024: $69.9/bbl).
The Company providing investors with direct exposure to the uranium market through our physical holding of uranium oxide concentrate (U3O8) and uranium-related commercial activities announces its annual results for the year ended 31 March 2024. Spot U3O8 price rose to a 16-year high of $107/lb in February 2024 and closed at $87.00/lb on 31 March 2024, a 72% increase compared to its close of $50.65/lb as at 31 March 2023. Holdings of 20.16m lb of U3O8 as at 31 March 2024. Net asset value of $1,883.6m (£6.88 per share) as at 31 March 2024 (2023: $1,035.3 million (£4.23 per share)). The Company expects the existing trends in the uranium market to remain in place in the year ahead, with continued spot price volatility on an upward price trend in the near- to medium-term with a strong bias towards the upside as the lack of mobile inventory takes hold, constraining near-term uranium supply availability.
The technology group that has developed a LiDAR wind sensor and software suite designed to efficiently and cost effectively increase the power output of electricity generating wind turbines announces that Non-Executive Director Gavin Manson will move to a temporary, flexible part-time Executive contract giving flexibility to support the business as required, with remuneration structured accordingly.
This document has been issued to you by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific entity and is not a personal recommendation to anyone. Recipients should make their own investment decisions based upon their own financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.
The information contained in this document is based on materials and sources that are believed to be reliable; however, they have not been independently verified and are not guaranteed as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information in this document nor should it be relied upon as such.
Any and all opinions expressed are current opinions as of the date appearing on this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.
This document is sent to you as market commentary only. As market commentary this document does not constitute any of (i) investment research and financial analysis or other forms of general recommendation relating to transactions in financial instruments for the purposes of the UK retained version of section B of annex I to Directive 2014/65/EU ("MIFID II Directive"); or (ii) investment research as defined in the UK retained version of article 36(1) of Commission Delegated Regulation 2017/565/EU made pursuant to the MIFID II Directive; or (iii) non-independent research (as such term is defined in the Financial Conduct Authority's Conduct of Business Sourcebook).
This document should not be relied upon as being an independent or impartial view of the subject matter. The individuals who prepared this document may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.
In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority's Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as "relevant persons"). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority's Conduct of Business Sourcebook.
Neither this document nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.
Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.
This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.
Disclaimer & Declaration of Interest
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.